797

Prof. Cho, head of the lung cancer center at Yonsei Cancer Hospital, "J INTS BIO's new oral administration 4th generation EGFR TKI 'JIN-A02' expected to be a game changer"

Retrieved on: 
Tuesday, June 21, 2022
EGFR, Targeted therapy of lung cancer, TKI, Therapy, Safety, Yonsei University, Survival, Serine, Exon, Brain, Recurrence, Cancer, Cysteine, Mutation, Standard of care, Lung cancer, 797, Patient, NSCLC, Toxicity, General of the branch, Multimedia, Pharmaceutical industry, Medical imaging

EGFR mutant lung cancer accounts for the largest proportion of all lung cancers.

Key Points: 
  • EGFR mutant lung cancer accounts for the largest proportion of all lung cancers.
  • Currently approved EGFR-targeted therapeutics include Iressa and Tarceva in the 1st generation, Giotrif in the 2nd generation, and Tagrisso and Leclaza in the 3rd generation.
  • What is your experience with the use of 3rd Generation EGFR TKI and what are your concerns?
  • Having participated in J INTS BIO's Advisory Board meetings and reviewing the data of their novel oral 4th generation EGFR TKI 'JIN-A02', what is your assessment?

Prof. Cho, head of the lung cancer center at Yonsei Cancer Hospital, "J INTS BIO's new oral administration 4th generation EGFR TKI 'JIN-A02' expected to be a game changer"

Retrieved on: 
Tuesday, June 21, 2022
EGFR, Targeted therapy of lung cancer, TKI, Therapy, Safety, Yonsei University, Survival, Serine, Exon, Brain, Recurrence, Cancer, Cysteine, Mutation, Standard of care, Lung cancer, 797, Patient, NSCLC, Toxicity, General of the branch, Pharmaceutical industry, Medical imaging

EGFR mutant lung cancer accounts for the largest proportion of all lung cancers.

Key Points: 
  • EGFR mutant lung cancer accounts for the largest proportion of all lung cancers.
  • What is your experience with the use of 3rd Generation EGFR TKI and what are your concerns?
  • If it has all these attributes, it is the 4th generation TKI that is urgently needed in clinical practice.
  • Having participated in J INTS BIO's Advisory Board meetings and reviewing the data of their novel oral 4th generation EGFR TKI 'JIN-A02', what is your assessment?

New Bitcoin Protocols Continue to Feature True Return Systems' 2018 Blockchain Patented Technologies

Retrieved on: 
Friday, September 24, 2021
Ethereum, U.S. Securities and Exchange Commission, Decentralized finance, Health, Intellectual property, Lawsuit, Unlock, 797, Ownership, Pharma, Awareness, The Center of Applied Data Science, Technology, Blockchain, NFT, Patent, Cryptocurrency

The universal goal for cryptocurrencies and digital money has been fast and safe protocols with high liquidity and low transaction costs.

Key Points: 
  • The universal goal for cryptocurrencies and digital money has been fast and safe protocols with high liquidity and low transaction costs.
  • Each of Bitcoin, Ethereum, Ripple and the newer protocols have accepted some mix of trade-offs across security, speed, and functionality.
  • Even early hybrid blockchain protocols which based their original efforts on trustless and distributed data sourcing, have now adopted persistent and tractable data storage.
  • Detailed information relating to the Patent, the technology, and other True Return System properties is available at truereturnsystems.com .